Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 12/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4535527 | 0.99 | ADRA1D (0.44) | ADRA1DADRA1AADRA1BDRD2 | |
| Phosphoric Acid SCHEMBL5330883 | 0.96 | ADRA1D (0.43) | ADRA1DADRA1AADRA1BDRD2 | |
| Succinic Acid SCHEMBL5328590 | 0.96 | ADRA1D (0.42) | ADRA1DADRA1AADRA1B | |
| Maleic Acid SCHEMBL5325181 | 0.95 | ADRA1D (0.42) | ADRA1DADRA1AADRA1BDRD2 | |
| Cadaverine Tartrate SCHEMBL5327784 | 0.95 | ADRA1D (0.42) | ADRA1DADRA1AADRA1BDRD2 | |
| Fumaric Acid SCHEMBL5325185 | 0.95 | ADRA1D (0.42) | ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5330901 | 0.91 | ADRA1A (0.41) | ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL14541002 | 0.86 | DRD2 (0.48) | ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL4519413 | 0.86 | DRD2 (0.48) | ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL4535333 | 0.85 | MEN1 (0.40) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | claimed |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | disclosed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | ADRA1D, ADRB1, ADRA1A | ADRA1D 1/4885ADRA1A 3/4885ADRA1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.